FDA-Drug2026-04-01Class IIPROCESSING DEFECT
Teva Octreotide Acetate injectable suspension recalled for sterility concerns
What this means
Teva Pharmaceuticals is recalling specific lots of Octreotide Acetate injectable suspension (20 mg) due to quality control issues at the manufacturing facility in Greece. The FDA found deficiencies that could affect sterility—the assurance that the medication is free from harmful bacteria and other microorganisms.
- Check your medication vial for lot numbers: 4401491, 4401600, 4401603, 4401629 (expiring 9/31/2026) or 4500594, 4500786, 4500920, 4501007, 4501462 (expiring 3/31/2027)
- If you have an affected lot, contact your pharmacy or prescriber immediately—do not use the medication
- Ask your doctor or pharmacist for a replacement from a non-recalled lot
The agency's original wording
Hazard
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
Intended for
Adults
Illnesses reported
None reported
Sold states
Nationwide in the USA
Affected count
19,869 Cartons
Manufactured in
400 Interpace Pkwy Bldg A, Parsippany, NJ, United States
Products
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9259-08.
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0405-2026More Teva recalls
- FDA-Drug2026-09-09Teva trazodone 50 mg tablets recalled for foreign tablets in bottles
Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.